Very late initiation of HAART impairs treatment response at 48 and 96 weeks: Results from a meta-analysis of randomized clinical trials

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 312-321

  Pérez molina, José A ^a   Díaz menéndez, Marta ^a   Plana, Marí N ^a   Zamora, Javier ^a   López vélez, Rogelio ^a   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antiretroviral therapy; Antiretrovirals; Meta analysis; Naive

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; DIDANOSINE PLUS LAMIVUDINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR PLUS EMTRICITABINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS (TOPIC); MIXED INFECTION; MORTALITY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; VERY LATE STARTER;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84855858793     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr478     Document Type: Review

References (57)

1. Atta MG, Gallant JE, Rahman MH et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006; 21: 2809-13.
2. Kalayjian RC, Franceschini N, Gupta SK et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22: 481-7.
3. Matthews GV, Avihingsanon A, Lewin SR et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48: 1062-9.
4. Peters MG, Andersen J, Lynch P et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44: 1110-6.
5. Avidan NU, Goldstein D, Rozenberg L et al. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr 2009; 52: 452-8.
6. Kovari H, Weber R. Influence of antiretroviral therapy on liver disease. Curr Opin HIV AIDS 2011; 6: 272-7.
7. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Updated 10 January 2011. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (25 April 2011, date last accessed).
8. Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero de 2011). http://www.gesida.seimc.org/pcientifica/dcconsensos.asp?apnv0=pcientifica&ap (25 April 2011, date last accessed).
9. Mills AM, Nelson M, Jayaweera D et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 1679-88.
10. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J AcquirImmuneDefic Syndr 2010; 53: 323-32.
11. Cassetti I, Madruga J, Etzel A et al. The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-nai{dotless}̈ve patients through seven years. In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, Mexico, 2008. Abstract TUPE0057.
12. Arribas JR, Pozniak AL, Gallant JE et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47: 74-8.
13. Murphy RL, da Silva BA, Hicks CB et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2008; 9: 1-10.
14. Pulido F, Estrada V, Baril JG et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials 2009; 10: 76-87.
15. Baker JV, Peng G, Rapkin J et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22: 841-8.
16. Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-63.
17. Emery S, Neuhaus JA, Phillips AN et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 1133-44.
18. Severe P, Juste MA, Ambroise A et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257-65.
19. The HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011; 154: 509-15.
20. Mussini C, Manzardo C, Johnson M et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 2008; 22: 2461-9.
21. Rockstroh JK, Gatell J, Landman R et al. Management of late-presenting patients with HIV infection. Antivir Ther 2010; 15 Suppl 1: 25-30.
22. Lanoy E, Mary-Krause M, Tattevin P et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007; 12: 89-96.
23. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
24. Lichtenstein KA, Delaney KM, Armon C et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32: 48-56.
25. Smith CJ, Olsen CH, Mocroft A et al. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS 2008; 22: 47-56.
26. Mocroft A, Phillips AN, Gatell J et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370: 407-13.
27. Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-26.
28. European Guidelines for Treatment of HIV Infected Adults in Europe. http://www.europeanaidsclinicalsociety.org/guidelines.asp (10 May 2010, date last accessed).
29. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Updated 1 December 2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (10 May 2010, date last accessed).
30. [AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)]. Enferm Infecc Microbiol Clin 2010; 28: 362.e1-91.
31. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
32. Zoufaly A, an der Heiden M, Kollan C et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis 2011; 203: 364-71.
33. Sauce D, Larsen M, Fastenackels S et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011; 117: 5142-51.
34. Heaton RK, Clifford DB, Franklin DR Jr et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010; 75: 2087-96.
35. Perez-Molina JA, Suarez-Lozano I, Del Arco A et al. Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status. HIV Clin Trials 2011; 12: 1-8.
36. Street E, Curtis H, Sabin CA et al. British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from naive. HIV Med 2009; 10: 337-42.
37. Chadborn TR, Delpech VC, Sabin CA et al. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006; 20: 2371-9.
38. Delpierre C, Lauwers-Cances V, Pugliese P et al. Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people. Eur J Public Health 2008; 18: 345-7.
39. Hansel A, Bucher HC, Nuesch R et al. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients. J Acquir Immune Defic Syndr 2001; 26: 191-3.
40. Sobrino-Vegas P, Garcia-San Miguel L, Caro-Murillo AM et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7: 224-30.
41. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
42. Aceti A, Pasquazzi C, Zechini B et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29: 41-8.
43. Wit FW, Weverling GJ, Weel J et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31.
44. Weis N, Lindhardt BO, Kronborg G et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006; 42: 1481-7.
45. 3in Mexico. J Acquir Immune Defic Syndr 2010; 53: 582-8.
46. Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-97.
47. van Leth F, Andrews S, Grinsztejn B et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19: 463-71.
48. Echeverria P, Negredo E, Carosi G et al. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naive patients: a 48-week, multicentre, randomized study (Lake Study). Antiviral Res 2009; 85: 403-8.
49. Molina JM, Podsadecki TJ, Johnson MA et al. A lopinavir/ ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007; 23: 1505-14.
50. Gathe J, da Silva BA, Cohen DE et al. A once-daily lopinavir/ ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009; 50: 474-81.
51. Gathe JC Jr, Ive P, Wood R et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18: 1529-37.
52. Berenguer J, Gonzalez J, Ribera E et al. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis 2008; 47: 1083-92.
53. Malan N, Krantz E, Neal D et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 107LB. Foundation for Retrovirology and Human Health, Alexandira, VA, USA.
54. Hicks CB, DeJesus E, Sloan LM et al. Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Hum Retroviruses 2009; 25: 395-403.
55. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-55.
56. Gonzáez-García J, Cohen D, Johnson M et al. Short communication. Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine+tenofovir DF in antiretroviral-naive, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730. AIDS Res Hum Retroviruses 2010; 26: 841-5.
57. Carosi G, Lazzarin A, Stellbrink H et al. Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/ lamivudine once daily in antiretroviral-naive HIV-1-infected adult subjects. HIV Clin Trials 2009; 10: 356-67.